Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.72 |
| ▸ | MAPT | P10636 | 11/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 9/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.72 |
| ▸ | MEN1 | O00255 | 8/20 | 0.72 |
| ▸ | USP2 | O75604 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.69 |
| ▸ | CASP3 | P42574 | 3/20 | 0.69 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.69 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.69 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10357439 | 0.91 | KMT2A (0.68) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL9911652 | 0.88 | RAB9A (0.74) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL10357789 | 0.86 | KMT2A (0.69) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL10357348 | 0.86 | ALOX15 (0.67) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL7998301 | 0.85 | MAPT (0.81) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL3594441 | 0.85 | MAPT (0.61) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL10358110 | 0.84 | MAPT (1.00) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL10358038 | 0.84 | KMT2A (0.79) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL10357743 | 0.83 | KMT2A (0.59) | HPGDMAPTALOX15KMT2AMEN1 | |
| SCHEMBL10358277 | 0.83 | MEN1 (0.83) | HPGDMAPTALOX15KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359126-B1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2024-04-17 | — | — | EP | claimed |
| US-11759467-B2 | Treatment | VERONA PHARMA PLC (GB) | 2023-09-19 | — | — | US | claimed |
| US-11352400-B2 | PI3K gamma inhibitor peptide for treatment of respiratory system diseases | KITHER BIOTECH SRL (IT) | 2022-06-07 | — | — | US | claimed |
| CN-113563451-A | Novel PI3K gamma inhibitor peptides for the treatment of respiratory diseases | 凯思生物技术公司 | 2021-10-29 | — | — | CN | claimed |
| CN-107406488-B | Novel PI3K gamma inhibitor peptides for the treatment of respiratory diseases | 凯思生物技术公司 | 2021-08-31 | — | — | CN | claimed |
| US-20210106585-A1 | NEW TREATMENT | VERONA PHARMA LIMITED (GB) | 2021-04-15 | — | — | US | claimed |
| US-20200317740-A1 | NOVEL PI3K GAMMA INHIBITOR PEPTIDE FOR TREATMENT OF RESPIRATORY SYSTEM DISEASES | KITHER BIOTECH SRL (IT) | 2020-10-08 | — | — | US | claimed |
| US-10730921-B2 | PI3Kγ inhibitor peptide for treatment of respiratory system diseases | KITHER BIOTECH S.R.L. (IT) | 2020-08-04 | — | — | US | claimed |
| US-20200206198-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2020-07-02 | — | — | US | claimed |
| EP-3658136-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | Raia, Valeria (IT) | 2020-06-03 | — | — | EP | claimed |
| WO-2019020663-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2019-01-31 | — | — | WO | claimed |
| US-20180086798-A1 | NOVEL PI3K GAMMA INHIBITOR PEPTIDE FOR TREATMENT OF RESPIRATORY SYSTEM DISEASES | KITHER BIOTECH SRL (IT) | 2018-03-29 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | claimed |
| EP-3231444-A1 | NEW TREATMENT | Verona Pharma PLC (GB) | 2017-10-18 | — | — | EP | claimed |
| US-20170112839-A1 | NEW TREATMENT | VERONA PHARMA LIMITED (GB) | 2017-04-27 | — | — | US | claimed |
| WO-2017060388-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2017-04-13 | — | — | WO | claimed |
| EP-3142701-A1 | NEW TREATMENT | Verona Pharma PLC (GB) | 2017-03-22 | — | — | EP | claimed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | claimed |
| WO-2015173551-A1 | NEW TREATMENT | VERONA PHARMA PLC (GB) | 2015-11-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106585-A1 | NEW TREATMENT | CFTR, LTC4S, FDPS | HPGD 1214/4885MAPT 4754/4885ALOX15 501/4885 |
| US-11759467-B2 | Treatment | CFTR, LTC4S, FPR1 | HPGD 1498/4885MAPT 4726/4885ALOX15 633/4885 |
| US-20170112839-A1 | NEW TREATMENT | CFTR, LTC4S, FDPS | HPGD 1214/4885MAPT 4754/4885ALOX15 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.